Analyst Price Targets — UTRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 9, 2022 8:39 pm | Matt O'Brien | Piper Sandler | $100.00 | $53.80 | TheFly | Minerva Surgical price target lowered to $5 from $6 at Piper Sandler |
Latest News for UTRS
INVO Fertility (NASDAQ: IVF - Get Free Report) and Minerva Surgical (NASDAQ: UTRS - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations. Institutional and Insider Ownership 12.0% of INVO
Valuation and Earnings This table compares Minerva Surgical and T2 Biosystems"s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Surgical $51.69 million 0.00 -$34.11 million ($8.21) 0.00 T2 Biosystems $7.68 million 0.01 -$50.08 million ($3.89) 0.00 Minerva Surgical has higher revenue and earnings than
Minerva Surgical (NASDAQ: UTRS - Get Free Report) and InspireMD (NYSE: NSPR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation. Valuation and Earnings This table compares Minerva Surgical
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for UTRS.
U.S. House Trading
No House trades found for UTRS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.